- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update – February 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Trospium chloride (Flotros®) has been accepted for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder. It is noted that this product is a lower cost alternative to an existing trospium preparation.

Aliskiren (Rasilez®) has been rejected for the treatment of essential hypertension. It is noted that blood pressure reductions are comparable to existing agents but effects on mortality and long-term morbidity are currently unknown. The clinical and economic analyses presented were insufficient to gain acceptance.

Sildenafil (Revatio®) has been restricted for use in patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II, to improve exercise capacity provided that treatment is initiated by specialists working in the Scottish Pulmonary Vascular Unit or similar specialists.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.